Evidence map›Paper›PMID 33028695›Full record

ArticleJournal for immunotherapy of cancer2020

Analysis of the molecular nature associated with microsatellite status in colon cancer identifies clinical implications for immunotherapy.

Xuanwen Bao, Hangyu Zhang, Wei Wu, Shaobing Cheng, Xiaomeng Dai, Xudong Zhu, Qihan Fu, Zhou Tong, Lulu Liu, Yi Zheng and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.

0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed
5.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

70 citing papers in PubMed, 91 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. MEX3A Modulates PPARγ Pathway Activity and Colorectal Cancer Growth.Cellular and molecular gastroenterology and hepatology · 2026
    Article
  6. Article
  7. Article
  8. Spatially resolved C1QCCell discovery · 2025
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Define a good prognosis ofFrontiers in oncology · 2025
    Article
  15. SPP1International journal of genomics · 2025
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

10 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Xuanwen Bao *Department of Medical Oncology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.ORCID 0000-0002-6232-3783
Hangyu Zhang *Department of Medical Oncology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Wei WuDepartment of Medical Oncology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Shaobing ChengDepartment of Colorectal Surgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Xiaomeng DaiDepartment of Medical Oncology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Xudong ZhuDepartment of Medical Oncology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Qihan FuDepartment of Medical Oncology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Zhou TongDepartment of Medical Oncology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Lulu LiuDepartment of Medical Oncology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Yi ZhengDepartment of Medical Oncology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Peng ZhaoDepartment of Medical Oncology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China fanlong_liu@zju.edu.cn weijiafang@zju.edu.cn zhaop@zju.edu.cn.
Weijia FangDepartment of Medical Oncology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China fanlong_liu@zju.edu.cn weijiafang@zju.edu.cn zhaop@zju.edu.cn.
Fanglong LiuDepartment of Colorectal Surgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China fanlong_liu@zju.edu.cn weijiafang@zju.edu.cn zhaop@zju.edu.cn.ORCID 0000-0002-3288-7262
Zhejiang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMicrosatellite instability in colon cancer implies favorable therapeutic outcomes after checkpoint blockade immunotherapy. However, the molecular nature of microsatellite instability is not well elucidated.

methodsWe examined the immune microenvironment of colon cancer using assessments of the bulk transcriptome and the single-cell transcriptome focusing on molecular nature of microsatellite stability (MSS) and microsatellite instability (MSI) in colorectal cancer from a public database. The association of the mutation pattern and microsatellite status was analyzed by a random forest algorithm in The Cancer Genome Atlas (TCGA) and validated by our in-house dataset (39 tumor mutational burden (TMB)-low MSS colon cancer, 10 TMB-high MSS colon cancer, 15 MSI colon cancer). A prognostic model was constructed to predict the survival potential and stratify microsatellite status by a neural network.

resultsDespite the hostile CD8

conclusionOur analysis unraveled the difference in the molecular nature and genomic variance in MSI and MSS colon cancer. The microsatellite status-related gene signature is better at predicting the prognosis of patients with colon cancer and response to the combination of immune checkpoint inhibitor-based immunotherapy and anti-VEGF therapy.

Indexed as

Colonic NeoplasmsFemaleHumansImmunotherapyMaleMicrosatellite InstabilityPrognosisSurvival AnalysisTumor Microenvironmentcomputational biologyimmunotherapytumor biomarkerstumor microenvironment

Identifiers

PMID33028695
PMCPMC7542666
OpenAlexW3092449327

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.